Compare PCRX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | ANAB |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2010 | 2015 |
| Metric | PCRX | ANAB |
|---|---|---|
| Price | $36.48 | $45.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $33.57 | ★ $87.25 |
| AVG Volume (30 Days) | ★ 958.5K | 367.2K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | 91.02 |
| EPS | ★ 0.89 | 0.11 |
| Revenue | ★ $541,533,000.00 | $234,603,000.00 |
| Revenue This Year | $3.84 | $28.82 |
| Revenue Next Year | $4.73 | $24.35 |
| P/E Ratio | ★ $40.96 | $420.73 |
| Revenue Growth | 26.04 | ★ 157.01 |
| 52 Week Low | $18.80 | $33.10 |
| 52 Week High | $36.67 | $73.30 |
| Indicator | PCRX | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 82.40 | 39.20 |
| Support Level | $22.00 | $44.25 |
| Resistance Level | $36.67 | $57.55 |
| Average True Range (ATR) | 0.04 | 1.82 |
| MACD | -0.37 | -0.05 |
| Stochastic Oscillator | 90.00 | 5.58 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).